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Aerobic organisms developed mechanisms to protect themselves against a shortage of oxygen (O2). Recent
studies reveal that O2 sensors, belonging to the novel class of 2-oxoglutarate dependent iron(ii)-dioxyge-
nases, have more important roles in metabolism than anticipated. Here, we provide a ‘‘metabolo-centric’’
overview of the role of the PHD/FIH members of this family in metabolism, in particular on how they regulate
O2 supply and consumption, energy compensation and conservation, O2 conformance and hypoxia toler-
ance, redox and pH homeostasis, and other vital metabolic processes with implications in health and
disease. These insights may offer novel opportunities for the treatment of ischemic diseases.The appearance of oxygen (O2) into the biosphere was one of the
defining moments in evolution, as it offered organisms the
advantage of generating energy more efficiently. According to
the ‘‘endo-symbiosis’’ theory (Greek for ‘‘living together’’), the
ancestors of mitochondria were bacteria, capable of respiring
O2, that survived endocytosis by other species. The ability of
symbiont bacteria to conduct cellular respiration in host cells,
relying otherwise on anaerobic fermentation, would have
provided a considerable evolutionary advantage for these hosts.
This imposed a strong selection pressure for organisms to
develop novel pathways of aerobic metabolism.
Because of the high energy potential of O2, aerobic organisms
have become dependent on this gas for their performance and
survival. Apart from its role in energy metabolism, O2 is also
utilized as a substrate for the production of cellular constituents,
including signaling mediators. Hence, aerobic species devel-
oped mechanisms to sense O2 levels and regulate O2 consump-
tion, in order to cope with conditions of insufficient O2 supply.
Since C. Scheele’s discovery, now more than 200 years ago,
of O2 as a gas ‘‘that made his chest feel peculiarly light,’’ recent
studies provide novel molecular insight as to how cells sense O2,
and how these O2 sensors regulate metabolism. In this Review,
we will discuss how a new class of O2 sensors has key roles in
reprogramming metabolism in response to changes in O2
tension, and discuss consequences for health and disease.
The Challenge of Fluctuating O2 Levels
Ischemic diseases, characterized by an imbalance in O2 demand
and supply, are leading causes of mortality worldwide. But even
in healthy conditions, cells are exposed to greatly varying levels
of O2. Not all cells in our body are exposed to the same level of
O2, with substantial differences in the partial pressure of O2
(PO2) in distinct anatomical sites and physiological conditions.
For instance, in most tissues, the PO2 varies between 20 to
45 mmHg (corresponding to 2.5–5.8 kPa) (Braun et al., 2001;
Erecinska and Silver, 2001; Ward, 2008), but in some tissue
compartments, such as the kidney medulla, bone marrow orintrauterine fetal compartment, the PO2 is even lower, ranging
between 10 to 25 mmHg (1.3–3.3 kPa) (Chow et al., 2001;
Leichtweiss et al., 1969; Singer and Muhlfeld, 2007). In solid
tumors, certain regions are even exposed to extreme hypoxia,
almost approximating anoxia (<0.1mmHg; 0.01 kPa) (Helmlinger
et al., 1997).
Another challenge is that O2 levels are not constant, but
fluctuate dynamically. It is therefore of vital importance that cells
are equipped with mechanisms that sense subtle changes in O2
tension to adjust metabolism to O2 supply. During evolution,
various mechanisms of O2 sensing have evolved (Ward, 2008).
In typical O2 sensing tissues, such as the carotid body, pulmo-
nary artery, and adrenal chromaffin cells, mitochondria likely
act as O2 sensors, possibly by using reactive oxygen species
(ROS), energy state, or cytosolic redox state as intermediate
signals (Ward, 2008); we will not discuss these mechanisms
here. Instead, we will focus on a novel class of O2-dependent
enzymes, that has been recently discovered as O2 sensors: in
mammals, this family consists of four distinct ‘‘prolyl hydroxylase
domain’’ (PHD) proteins, and a single asparaginyl hydroxylase
called ‘‘factor inhibiting HIF’’ (FIH) (Bruick and McKnight, 2001;
Epstein et al., 2001; Koivunen et al., 2007; Lando et al., 2002).
We will now describe their molecular properties.
PHDs/FIH and HIF: The Molecular Players
The hypoxia-inducible transcription factors (HIF-1a, -2a, -3a) are
key mediators of the cellular transcriptional response to hypoxia.
Under hypoxic conditions, protein levels of the HIFa subunits
rapidly increase; after translocation to the nucleus, they hetero-
dimerize with their HIFb subunit partner and enhance transcrip-
tion of a large number of genes (Pouyssegur et al., 2006;
Semenza, 2007). This program includes genes, involved in meta-
bolic adaptation to low O2 tension, including energy compensa-
tion, oxygen conformance, hypoxia tolerance, redox and pH
homeostasis, O2 supply, as well as many others processes (Se-
menza, 2003; Simon and Keith, 2008; Weidemann and Johnson,
2008) (Figure 1). An extensive list of genes, identified as targetsCell Metabolism 9, January 7, 2009 ª2009 Elsevier Inc. 11
Figure 1. Molecular and Biological Properties of PHD/FIH
As an example for the PHDs/FIH, the three-dimenstional structure of murine PHD2 (amino acids 188–404) is shown, with its catalytic site (inset, left panel)
containing the His-X-Asp/Glu-Xn-His triad required for docking of Fe
2+, O2, 2-oxoglutarate (2-OG) and target HIFa amino acid residues, i.e., proline (Pro) for
PHDs and asparagine (Asn) for FIH. In their hydroxylated form, HIFs are targeted for proteasomal degradation (in the case of Pro hydroxylation by PHDs) or loose
transcriptional activity (Asn-hydroxylation by FIH); in contrast, upon inactivation of PHDs/FIH under low O2 conditions, nonhydroxylated HIFa subunits stimulate
transcription of a genetic program, leading to alterations oxygen supply and metabolism (other biological processes activated by HIFs are not listed).
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previously reviewed (Semenza, 2003).
HIFa subunits do, however, not sense O2 directly; this activity
is performed by PHDs and FIH. PHDs and FIH are 2-oxoglutarate
dependent iron(ii)-dioxygenases, which use one of the atoms of
O2 to hydroxylate prolyl or asparaginyl residues, respectively
(Kaelin and Ratcliffe, 2008; Lando et al., 2003; Schofield and Rat-
cliffe, 2004) (Figure 1). The second atom of O2 is used to convert
2-oxoglutarate to carbon dioxide (CO2) and succinate. Iron
(Fe2+),maintained in a reduced state by ascorbate, is a necessary
cofactor. PHDs hydroxylate N- and C-terminal prolyl residues in
HIFa subunits (Schofield and Ratcliffe, 2004). When the prolyl
residues are hydroxylated in conditions of sufficient oxygen
supply, HIFa subunits are recognized by the von Hippel-Lindau
(vHL) protein in the multiprotein E3 ubiquitin ligase complex;
through ubiquitination, this complex marks HIF proteins for
subsequent degradation by the proteasome machinery (Safran
and Kaelin, 2003; Schofield and Ratcliffe, 2004). FIH hydroxyl-
ates a C-terminal asparagyl residue in HIF-1a, which impairs
interaction with the coactivator p300, that is essential for the
transcriptional activity of HIF-1a (Lando et al., 2003) (Figure 1).
When the O2 supply drops, PHDs and FIH become progressively
inactive, resulting in stabilized (elevated) levels of transcription-
ally active HIF complexes (Figure 1).
Despite their relatively low affinity for O2, with a KM (100–
250 mM for PHDs; 90 mM for FIH) (Ehrismann et al., 2007; Koivu-
nen et al., 2004) that is much higher than tissue PO2 levels
(Gnaiger et al., 1998; Ward, 2008), PHDs/FIH have a sufficient12 Cell Metabolism 9, January 7, 2009 ª2009 Elsevier Inc.dynamic response over the physiological range of PO2 levels
(Ward, 2008). Also, in cellulo, their overall activity is not only
determined by the PO2, but also by the availability of 2-oxogluta-
rate (cosubstrate), Fe2+ (cofactor), and other substituents such
as mitochondrial ROS and ascorbate (Kaelin and Ratcliffe,
2008). These enzymes differ in their affinity for O2. With FIH
having a higher affinity for O2 than PHDs, FIH remains active at
reduced O2 tensions, when PHDs have already lost their activity.
This allows cells to activate different sets of genes in response to
various degrees of hypoxia and thereby fine-tune the hypoxia
response (Dayan et al., 2006; Koivunen et al., 2004).
Here, we will focus our discussion on how PHDs/FIH regulate
metabolism and how, through such metabolic effects, they influ-
ence biological processes in health and disease. For further
information about the molecular properties and regulation (for
instance, by nitric oxide and ROS), expression pattern, and other
targets of PHDs/FIH, the reader is referred to previous overviews
(Berra et al., 2006; Cash et al., 2007; Kaelin and Ratcliffe, 2008).
Role of PHDs in Oxygen Supply
For cells to generate energy aerobically, they must receive O2.
Hence, when challenged with hypoxia, mechanisms come into
action to restore oxygenation. Divergent taxa developed distinct
mechanisms to improve O2 carrying capacities in conditions of
O2 starvation. For instance, the water flea Daphnia produces
more hemoglobin, while the avascular fruitfly Drosophila, which
carriesO2 to distant cells via airways, expands its airway network
(Gorr et al., 2006). Vertebrates, which use hemoglobin-rich
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vessels, stimulate angiogenesis, vasodilation, erythropoiesis, and
ventilation. Screening of subjectswith idiopathic erythrocytosis re-
vealed two heterozygous mutations in the PHD2 gene (P317R,
R371H) that decrease enzyme activity (Percy et al., 2006, 2007).
Consistent herewith, mice with targeted disruption of PHD2 after
birth have reducedPHD2activity in various adult tissues (including
kidney), resulting in the upregulation of renal erythropoietin levels
and the development of polycythemia (Minamishima et al., 2008;
Takeda et al., 2008). The other PHD isoforms are also involved,
as combined loss of PHD1 and PHD3 in mice induces mild eryth-
rocytosis through enhanced erythropoiesis in the liver, though,
intriguingly, the pattern of activation of erythropoietin differs from
that in PHD2 deficient mice (Takeda et al., 2008).
PHD2 has also been implicated in angiogenesis, though only
to a limited extent so far. Indeed, postnatal disruption of PHD2
in the heart, lung, kidney, and liver increases the number and
size of blood vessels in these tissues (Takeda et al., 2007).
Enhanced angiogenesis was also observed in the brain of these
animals, despite inefficient disruption of the PHD2 allele in this
tissue, suggesting that the increase in angiogenesis in these
mice might be mediated by circulating rather than locally
produced angiogenic factors (Takeda et al., 2007). These mice
die, however, prematurely because of circulatory congestion
and dilated cardiomyopathy, indicating the need for tight regula-
tion of the cardiovascular system by PHD2 (Minamishima et al.,
2008). Silencing of PHD2 in vitro stimulates the proliferation of
endothelial cells, at least of immortalized cells (Takeda and
Fong, 2007). Recent studies indicate that partial loss of PHD2
in endothelial cells results in normalization of the endothelial
layer in tumor vessels (M. Mazzone, D. Dettori, R. Leite de Oli-
veira, S. Loges, T. Schmidt, B Jonckx, Y.M. Tian, A.A. Lanahan,
P. Pollard, C. Ruiz de Almodovar, F. De Smet, S. Vinckier, J.A., A.
Luttun, S. Wyns, B. Jordan, A. Pisacane, B. Gallez, M.G. Lamp-
ugnani, E. Dejana, M. Simons, P. Ratcliffe, P. Maxwell, and P.C.,
unpublished data). None of these alterations was observed in
mice lacking PHD1 or PHD3 (Takeda et al., 2007). Numerous
studies also document a key role of HIFs in angiogenesis in
health and disease (Carmeliet and Jain, 2000; Harris, 2002). By
switching on a genetic program of angiogenic and arteriogenic
factors, HIFs induce the formation of a mature, stable, and func-
tional neovasculature (Carmeliet and Jain, 2000). Preclinical
studies further reveal thatHIF-1a gene transfer stimulates revas-
cularization and improves functional recovery of ischemic
tissues (Vincent et al., 2000). Therefore, given the involvement
of HIFs in angiogenesis, the vascular changes in PHD2 mutant
mice are likely due to activation of HIFs. It remains, however,
to be determined whether HIF-1a or HIF-2a are downstream of
PHD2, since each of these HIFs seems tomediate distinct angio-
genic processes (Ohneda et al., 2007; Tang et al., 2004).
PHDs/FIH Safeguard Cellular Metabolism
via Energy Compensation
PHDs/FIH act as safeguards of cellular metabolism. Because of
their relatively low affinity for O2, they already initiate a defense
before O2 levels drop too low, which would otherwise lead to
cellular demise (Koivunen et al., 2004). Hence, PHDs/FIH start
to progressively lose activity when tissue PO2 levels drop over
a physiological range (Bracken et al., 2006; Wiesener et al.,1998), while mitochondrial respiration will only arrest when O2
tension drops to very low levels, i.e., below 1 mmHg (Gnaiger
et al., 1998). This safeguard activity of the O2 sensors allows
the cell to adapt to hypoxia, without becoming completely
deprived of energy and challenged with life-threatening exhaus-
tion of vital ATP.
A metabolic adaptation to hypoxia involves that cells switch
from aerobic to anaerobic metabolism (‘‘Pasteur effect’’)
(Figure 2). With this energy compensation, the cell can continue
to generate ATP and, despite the hypoxia, try to meet the meta-
bolic demands and maintain energy expenditure of normoxic
conditions. The O2 sensors, in conjunction with HIFs, regulate
various aspects of this metabolic adaptation. Upon O2 depriva-
tion, HIF-1a stimulates the glycolytic flux through upregulation
of key glycolytic genes, including the glucose transporters
GLUT1 and GLUT3, the hexokinases HK1 and HK2, and lactate
dehydrogenase (LDH) (Iyer et al., 1998). In cancer cells, HIF-1a
also cooperates with c-Myc to promote aerobic glycolysis by
induction of hexokinase HK2 and the pyruvate dehydrogenase
kinases PDK1 (Dang et al., 2008). Through phosphorylation,
PDKs inhibit the activity of the pyruvate dehydrogenase complex
(PDC), a key enzyme regulating the entry of pyruvate in the TCA
cycle through conversion to acetyl CoA (Kim et al., 2006; Papan-
dreou et al., 2006). A recent study also documents the role of the
PDK3 isoform in this metabolic adaptation in cancer cells (Lu
et al., 2008).
To prevent intracellular acidification during glycolysis, HIFs
also drive expression of monocarboxylic transporters (MCT)
and Na+/H+ exchanger-1 (NHE-1), that mediate lactate and
proton efflux (Pouyssegur et al., 2006; Shimoda et al., 2006; Ul-
lah et al., 2006) (Figure 2). Another key regulator of pH homeo-
stasis, whose expression is induced in hypoxic conditions,
includes carbonic anhydrase 9 (CAIX) (Pouyssegur et al., 2006;
Wykoff et al., 2000). This extracellular enzyme catalyzes the
conversion of CO2 and H2O to HCO3
 (bicarbonate) and H+
(protons); HCO3
 exchangers then import extracellular bicar-
bonate into the cytosol, thereby further preventing intracellular
acidification.
PHDs promote the shift to anaerobic metabolism also by
sensing alterations in the levels of glycolytic and TCA cycle
metabolites. For instance, glycolytic intermediates, such aspyru-
vate and lactate, but also TCA intermediates, such as oxaloace-
tate andmalate, inhibit PHDs/FIH, possibly by acting as compet-
itive antagonists for 2-oxoglutarate binding or by uncoupling
enzyme reactions that lock PHDs into inactive states; this stabi-
lizes HIFs, and reinforces the glycolytic flux (Lu et al., 2005).
Moreover, accumulation of fumarate and succinate also reduces
the activity of the PHDs, resulting in enhanced HIF signaling, as
has been documented in certain cancer cells with loss-of-func-
tion mutations of fumarate hydratase (FH) or succinate dehydro-
genase (SDH)-B (Isaacs et al., 2005; Selak et al., 2005).
Genetic studies in mice established the in vivo role of PHD1 in
the above described mechanisms. Indeed, in the absence of
PHD1, glycolytic flux is enhanced in ischemic muscle fibers;
yet, these cells do not suffer lifethreatening acidosis in situ
upon ligation of their blood supply (Aragones et al., 2008)
(Figure 3). Molecular studies indicate that these metabolic and
pH changes are attributable to several mechanisms (Aragones
et al., 2008). Expression analysis reveals that loss of PHD1Cell Metabolism 9, January 7, 2009 ª2009 Elsevier Inc. 13
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Figure 2. PHDs/HIFs Regulate Energy Compensation in Hypoxic Conditions
(A) In normoxia, glucose, taken up by its transporters (blue cylinder), is metabolized to pyruvate through glycolysis, yieldingmodest amounts of ATP (yellow stars).
Pyruvate is then either converted to lactate, which exits the cell throughmonocarboxylate transporters (green cylinder), or enters the tricarboxylic acid (TCA) cycle
in mitochondria (Mi), yielding electrons (e), that are used to generate high amounts of ATP in oxidative phosphorylation (OXPHOS). Mitochondrial biogenesis
(indicated by the set of small mitochondria, lower left corner) promotes oxidative metabolism.
(B) In hypoxia, activation of HIF signaling by inactivation of PHDs initiates the illustrated changes in energy compensation and conservation. Oxygen conservation
(lower box): O2 consumption is reduced at the expense of mitochondrial energy production, resulting from (1) blocking entry of pyruvate (Pyr) into the TCA cycle
via induction of pyruvate dehydrogenase kinase (PDK), (2) reducing expression of succinate dehydrogenase subunit B (SDH-B), (3) lowering the amount of mito-
chondria by attenuating mitochondrial biogenesis or increasing autophagy, or (4) switching cytochrome c oxidase subunits (COX-4) to optimize efficiency of
respiration. Using fumarate as an alternative terminal electron acceptor can bypass the lack of O2. Energy compensation (upper box): to compensate for the
loss ofmitochondrial ATP production, anaerobic glycolysis is switched on. The glycolytic end products lactate and protons (H+), causing intracellular acidification,
are exported by MCTs (green cylinder) and NHE-1 (yellow cylinder). CAIX (red circle) generates extracelular HCO3 that is imported by HCO3 exchangers (gray
cylinder), thereby further preventing intracellular acidification. Increased glucose (Glu) uptake and conversion of pyruvate (Pyr) to lactate (Lac) by LDH, generating
the necessary cofactor NAD+, fuels glycolysis.in myofibers upregulates the levels of the pyruvate dehydroge-
nase kinase isoforms PDK1 and PDK4, which reduces the entry
of pyruvate in the TCA cycle. Second, LDH levels are upregulated
in PHD1-deficient myofibers, resulting in a greater conversion of
pyruvate to lactate. An advantage hereof is that NAD+ is continu-
ously being regenerated from NADH, thereby replenishing the
supply of this essential cofactor for glycolysis and maintaining
a high glycolytic flux. Since PHD1 deficiency also elevates the
expression of the lactate transporter MCT4, lactate efflux is facil-
itated, preventing severe cellular acidification. Hence, despite an
increased glycolytic flux in baseline conditions, the [lactate/pyru-
vate] ratio in ischemic conditions remains relatively low in
ischemic PHD1-deficient compared to wild-type cells. Notably,
PHD1-deficient myofibers enhance glycolytic flux without an
apparent upregulation of various HIF-1a-dependent genes,
such as the glucose transporter GLUT-1, the muscle-specific
form of phosphofructokinase (PFK-M), phosphoglycerate kinase
(PGK),M2-pyruvate kinase (PKM2), and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), possibly because HIF-2a is
a more important mediator of the PHD1 deficient metabolic
phenotype (see below).14 Cell Metabolism 9, January 7, 2009 ª2009 Elsevier Inc.Another condition, in which loss of function of PHDs (either re-
sulting from somaticmutations inPHD2 or epigenetic silencing of
PHD1) has been associated with similar metabolic changes, is
the malignant cancer cell (Calvisi et al., 2007; Kato et al., 2006).
Indeed, by modulating the levels of HIFs, PHDs/FIH can regulate
‘‘aerobic glycolysis’’ (Warburg effect) in tumor cells at various
steps, i.e., through an enhancement of glycolytic flux, restriction
of TCA cycle-mediated respiration, and pH homeostasis (all dis-
cussed above). Another metabolic adaptation of tumors is that
HIFs promote the production of lactate by tumor cells (through
upregulation of LDH); released lactate is then taken upby stromal
cells (through upregulation of MCTs), which then regenerate
pyruvate (through increased levels of LDH) as internal fuel for
glucose oxidation, or as external fuel for the cancer cell, as part
of a micro-ecosystem (Gatenby and Gillies, 2008). It has been
postulated that these metabolic changes offer tumor cells the
advantage to generate more ATP and survive in conditions of
fluctuating O2 levels that would otherwise kill normal cells; tumor
cells may also benefit from an acidicmicroenvironment (resulting
from glycolytic generation of lactate) that provides a growth
advantage; also, by shifting to aerobic glycolysis and reducing
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oxidative stress (DeBerardinis et al., 2008; Gatenby and Gillies,
2008; Kroemer and Pouyssegur, 2008). Alternative metabolic
adaptations of tumor cells include their hypoxia tolerance and
oxygen conformance (see below).
PHDs/FIH Regulate Oxygen Consumption
through Glucose Oxidation
Mitochondrial respiration relies on the availability of O2; hence,
mechanisms developed to slow down respiration in conditions
of hypoxia. PHDs/FIH regulate this process, at least in part,
through HIFs (Figure 2). Indeed, when PHDs/FIH are completely
inhibited, O2 consumption is reduced to 15% of baseline rates
in neonatal cardiomyocytes (Sridharan et al., 2008). HIFs reduce
mitochondrial O2 consumption by attenuating glucose oxidation.
At the molecular level, HIFs upregulate the expression of PDKs,
and thereby restrict the entry of the glycolytic intermediate pyru-
vate in the TCA cycle (Kim et al., 2006; Papandreou et al., 2006).
HIFs also regulate the expression of the respiratory enzyme
cytochrome c oxidase (COX). By inducing a switch from isoform
COX4-1 to COX4-2, HIF-1a and HIF-2a optimize the efficiency of
respiration at low O2 tension (Fukuda et al., 2007). Further, HIF-
1a lowers the expression of the mitochondrial SDH-B subunit
(Dahia et al., 2005). It also inhibits mitochondrial biogenesis, by
counteracting c-Myc, which enhances mitochondrial biogenesis
via induction of PGC-1b (Zhang et al., 2007). Once cells can no
longer generate sufficient ATP for survival, they turn to a form
of ‘‘self cannibalism’’ termed autophagy; by inducing this
program through upregulation of BNIP-3, HIF-1a reduces mito-
chondrial content and thereby lowers oxidative metabolism
(Zhang et al., 2008). Moreover, HIF-1a upregulates the expres-
sion of type3 deiodinase (DIO3), which inactivates 3,5,30-triiodo-
thyronine (T3) and decreases thyroid hormone-induced O2
consumption in cultured cell lines (Simonides et al., 2008).
From the above, it is clear that PHDs/FIH are key regulators of
O2 consumption. However, cells can recruit another mechanism
of metabolic adaptation when challenged by severe O2 depriva-
tion, which has been observed in muscle in diving mammals, or
in anoxic myocardium. Indeed, when PHDs/FIH are completely
inhibited, some cells can switch to fumarate as an alternative
terminal electron acceptor at complex II in the electron transport
chain, allowing their mitochondria to maintain membrane polar-
ization (Sridharan et al., 2008) (Figure 2). When PHDs are
completely inhibited, certain cells are capable of hybrid respira-
tion, utilizing O2 for respiration when available, but switching to
fumarate when oxidative respiration is paralyzed.
Genetic studies in mice reveal that PHD1 indeed controls O2
consumption (Aragones et al., 2008) (Figure 3). Indirect calori-
metry measurements show that whole body O2 consumption is
reduced in PHD1-deficient mice. As skeletal muscle constitutes
40%–50% of the body mass and is responsible for 40%–50% of
the O2 consumption in resting conditions, these data suggest
that O2 consumption in PHD1-deficient muscle is reduced.
Indeed, high-resolution respirometry of permeabilized muscle
fibers reveals that mitochondrial respiration through complex I
is reduced in PHD1-deficient myofibers. The reduced O2
consumption is not attributable to differences in mitochondrial
biogenesis, O2 delivery, erythropoiesis, vascularization, or perfu-
sion of muscles. Instead, in vivo 13C-NMR measurements of[13C] glutamate resonances in muscle extracts after infusion of
[U-13C6] glucose indicate that glucose oxidation is 35% lower
in PHD1-deficient mice, consistent with the increased expres-
sion of PDK1 and PDK4 in muscle of these mice (see above).
Ex vivo analysis using isolated muscles confirms that oxidation
of [U-14C] glucose is reduced in the absence of PHD1. Moreover,
HIFs are downstream effectors of PHD1 in this metabolic regula-
tion, since heterozygous deficiency of HIF-2a (and, to a lesser
extent, of HIF-1a) nullifies the PHD1-deficient reprogramming
of metabolism (Aragones et al., 2008).
Do PHDs/FIH Regulate Fatty Acid Oxidation?
Another important determinant of O2 consumption is fatty acid
oxidation; it remains, however, outstanding whether and how
PHDs/FIH regulate this process as well. 13C-NMR measure-
ments of [13C] glutamate resonances in muscle extracts after
whole animal infusion of [U-13C] fatty acids show that fatty acid
oxidation is not altered in the absence of PHD1 (Aragones
et al., 2008). This is somewhat surprising, since loss of PHD1 up-
regulates levels of PDK4 through PPARa activation (Aragones
et al., 2008), amaster regulator ofmetabolism that normally stim-
ulates fatty acid oxidation at the expense of glucose oxidation
(Lefebvre et al., 2006). The minimal role of PPARa in fatty acid
oxidation in PHD1-deficient muscle may be explained by several
reasons. First, PPARa levels are elevated in PHD1-deficient
muscle (Aragones et al., 2008), but perhaps, this upregulation
suffices to induce a shift in oxidative metabolism of glucose
but not of fatty acids. Indeed, even supraphysiological levels of
PPARa in skeletal muscle increase palmitate oxidation only by
1.5-fold (Finck et al., 2005). Second, in contrast to other organs,
such as heart and liver, fatty acid oxidation in skeletal muscle is
mainly controlled by PPARd (Schuler et al., 2006), the expression
of which is not altered in PHD1-deficient myofibers (Aragones
et al., 2008). In addition, in other cell types, hypoxia downregu-
lates the expression of PPARa or RXR, the obligate binding
partner of PPARa, or reduces the DNA binding activity of the
PPARa/RXR complex; these changes lower the levels of carni-
tine palmitoyltransferase I (CPT-I), the rate-limiting step in mito-
chondrial import of fatty acids for b oxidation; some of these
effects are mediated by HIF-1a (Huss et al., 2001; Narravula
and Colgan, 2001). Whether HIF-1a (by inhibiting PPARa
signaling) counteracts the HIF-2a-driven upregulation of PPARa
in PHD1-deficient mice, remains to be further explored.
Another intriguing question is whether PHDs/FIH are involved
in hibernation. Indeed, similar to the PHD1-deficient state, hiber-
nation relies, in part, on the induction of PDK4 and PPARa, and is
also associated with attenuated glucose oxidation (Carey et al.,
2003). Different from the PHD1-deficient mouse model,
however, certain hibernating species combust their fat stores
(Figure 4). In these species, induction of PPARa promotes lipid
oxidation (Carey et al., 2003), presumably because levels of
essential fatty acids, natural PPARa ligands, are elevated in
hibernating species (Carey et al., 2003); this does not occur
in PHD1 deficient mice, as their circulating fatty acids remain
normal in fed conditions (Aragones et al., 2008).
Control of Oxygen Conformance by PHDs/FIH
Oxygen conformance refers to the ability of cells, upon exposure
to insufficient O2, to reduce energy expenditure, which allowsCell Metabolism 9, January 7, 2009 ª2009 Elsevier Inc. 15
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Figure 3. Loss of Phd1 Induces Hypoxia Tolerance
(A and B) Histopathology of gastrocnemius muscle 2 days after induction of hindlimb ischemia. Hematoxylin-eosin (HE) staining shows extensive coagulation
necrosis and inflammatory cell infiltrates in wild-type muscle (A) but entirely healthy myofibers in ischemic PHD1 deficient muscle (B).
(C and D) Hematoxylin-eosin staining of heterozygous PHD1-deficient limb muscles (at 48 hr after ischemia) after shRNA-mediated knockdown of PHD1 (D) or
electroporation with amismatched shRNA-control construct (C) reveals protection against muscle necrosis upon knockdown of PHD1, but not in control-injected
heterozygous PHD1-deficient muscle.
(E) Baseline energy metabolism in wild-type myofibers: ATP is generated by anaerobic glycolysis (cytosol) and by glucose oxidation in the TCA cycle (mitochon-
drial matrix; MX), where it provides electrons (e) for themitochondrial electron-transport chain (ETC; yellow) that consequently drives the synthesis of ATP by the
ATP synthase (red).
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Figure 4. Role of PHDs and HIFs in Oxygen Conformance
(A) In normal metabolic conditions, a high level of energy expenditure ismatched by a high level of energy generation. Depending on the cell type, ATP (yellow star)
is generated glycolytically or oxidatively (an example of an oxidative cell type is shown for illustration; right box); ATP is consumed to ADP (yellow sphere) for
protein synthesis, channel function, and other ATP-demanding processes (left box).
(B) During oxygen conformance, energy expenditure is reduced, in part because hypoxic activation of HIF inhibits overall protein synthesis by inhibiting mTOR
signaling, thereby sparing ATP (left box). Cells also reduce O2 consumption by lowering entry of glycolytic intermediates (via PDK) and reducing TCA flux and
respiration (see Figure 2 for more explanation; right box). Depending on the species, glycolysis is compensatorily increased (Pasteur effect, as in PHD1-deficient
mice or anoxia tolerant turtles) or remains unchanged (reverse Pasteur effect, as in Mytilus mussels), while in other species, PPARa-driven fatty acid oxidation
(FAO) generates residual ATP in states of oxygen conformance (for instance, in hibernating grizzly bears). The reduced O2 consumption also lowers production of
ROS, while oxidative stress is further counteracted by increased antioxidant defense. Symbols and abbreviations: glucose (purple hexagons), ATP (yellow stars),
ADP (yellow spheres), mTOR, mammalian target of rapamycin; Pyr, pyruvate; PDK, pyruvate dehydrogenase kinase; PPARa, peroxisome proliferator-activated
receptor a; TCA cycle, tricarboxylic acid cycle; HIF, hypoxia inducible factor; ROS, reactive oxygen species.them to lower O2 consumption in advance of an energetic crisis.
Such energy conservation enhances survival at low O2 tension,
and induces a state of hypoxia tolerance. Several species,
such as fossorial or diving animals, estivating reptiles, hiber-
nating mammals, and dormant C. elegans dauer larvae, or
various invertebrates survive conditions of limiting O2 supply,
in part because of such metabolic depression (Ramirez et al.,
2007). An extreme example is the crustacean Daphnia, which
remains fully viable throughout a 24 hr anoxic challenge. But hu-
mans also show signs of oxygen conformance. For instance,
hypoxia tolerance in highlanders or in the fetus, both exposed
to low O2 tension, results from reductions in O2 demand. It has
been postulated that fetal hypoxia tolerance is an adaptation ofthe neonate brain to resist the threats of low O2 tension during
the birth process.
In many cases, this hypometabolic state results from reduced
glucose oxidation with a compensatory increase in anaerobic
glycolysis. For instance, imaging studies reveal lower cerebral
glucose utilization in Andean highlanders than lowlanders. Fetal
hypoxia tolerance is also characterized by reduced glucose
metabolism, with an associated increase in glucose transport,
glycolytic enzymes, and glycogen stores (Singer and Muhlfeld,
2007). In some hypoxia tolerant invertebrates (such as intertidal
Mytilus mussels or Cardium cockles), energy expenditure in
hypoxic conditions drops so low that there is even no need for
a compensatory increase in anaerobic glycolysis to generate(F and G) Lethal response to hypoxia in ischemic wild-type myofibers. As a result of the reduced O2 supply, oxidative phosphorylation is reduced. Nonetheless,
ischemic wild-type myofibers continue to consume O2, thereby generating excess ROS within the ETC (F). This increase in oxidative stress inactivates TCA and
ETC enzymes (red line) during prolonged ischemia (G), ultimately causing irreversible mitochondrial damage (cristolysis, indicated by dotted line) and complete
shutdown of oxidative energy metabolism. Anaerobic glycolysis cannot compensate for the loss of oxidative ATP production, leading to cellular energy exhaus-
tion and demise.
(H) Baseline metabolic reprogramming in PHD1-deficient myofibers. Enhanced expression of PDK4 reduces glucose oxidation and O2 consumption in PHD1
deficient myofibers. Coincidently, loss of PHD1 stimulates glycolytic production of ATP.
(I and J) Hypoxia tolerance in PHD1deficientmyofibers. ReducedO2 consumption leads to attenuated ROS formation in ischemic PHD1 deficient myofibers (I). As
a consequence, enzymes in the TCA and ETC are not (or are less) inactivated (J), thereby enabling residual oxidative phosphorylation (albeit lower than in baseline
conditions because of the reduced O2 supply). In addition, increased glycolysis together with the residual respiration provides sufficient ATP for survival. WT,
wild-type. Adapted from Aragones et al. (2008).
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ReviewATP for survival (‘‘reverse Pasteur effect’’). As a result of the
hypometabolic state, O2 consumption is accordingly reduced,
often more than 10-fold in hypoxia tolerant species (Andrews,
2002; Ramirez et al., 2007) (Figure 4).
Recent evidence implicates O2 sensors as regulators of O2
conformance. Indeed, pharmacological inhibition of PHDs/FIH
or genetic loss of PHD1 lowers O2 consumption in cardiomyo-
cytes and skeletal muscle cells, respectively, in vitro and
in vivo (Aragones et al., 2008; Sridharan et al., 2007; Sridharan
et al., 2008). This adaptation is caused, at least in part, by a re-
programming of basal metabolism, in particular by a reduction
of oxidative glucose metabolism due to an upregulation of
PDK1 and PDK4, which restrict the entry of glycolytic intermedi-
ates in the TCA cycle (see above) (Aragones et al., 2008) (Figures
3 and 4). Concomittant with the reduced O2 consumption, oxida-
tive muscle performance in PHD1-deficient mice is impaired,
suggesting that not only mechanisms to reduce energy genera-
tion, but also to reduce energy expenditure are operational in
PHD1/ myofibers (Aragones et al., 2008). Indeed, they fatigue
more rapidly when forced to run uphill, an exercise endurance
test that recruits primarily oxidative muscle fibers and relies on
oxidative metabolism. Loss of PHD1 does, however, not cause
an extreme O2 conformance program (as seen in water fleas
and mussels), since it compensatorily upregulates glycolytic
flux (Aragones et al., 2008). HIF-2a (and, to a lesser extent,
HIF-1a) is a downstream effector of PHD1 in the hypometabolic
adaptation (Aragones et al., 2008).
Another example of O2 conformance, in which HIF/PHD
signaling has been implicated, is the hibernating myocardium:
to save energy and match the reduced blood supply, the chronic
ischemic myocardium depresses oxidative metabolism,
contractility, and pump function (Heusch et al., 2005). In amouse
model of myocardial hibernation, increased HIF levels drive
a cardioprotective genetic program, that enhances glycolysis,
through upregulation of GLUT-1 and key glycolytic enzymes,
including triphosphate isomerase (TPI-1), pyruvate kinase (PK),
and GAPDH (May et al., 2008). Furthermore, the expression of
motor proteins (myosin 1B and tropomodulin 4), ion pumps,
and channels (KCNIP2, KCNJ3, KCNJ8, and ATP1A2) is down-
regulated, while KCNE4, an inhibitory subunit of potassium
currents, is increased (May et al., 2008). Also, hibernating cardi-
omyocytes elevate levels of natriuretic peptides and adrenome-
dullin, cardioprotective factors that reduce cardiac load by
promoting vasodilation and diuresis. Moreover, levels ofBNIP-3,
a HIF-inducible gene, are upregulated, resulting in autophagy of
hibernating cardiomyocytes. PHD3 expression is also upregu-
lated, presumably in a hypoxia-driven feedback to keep HIF
levels in check (May et al., 2008).
PHDs and HIFs not only control the switch to reduced energy
generation, but they may also regulate the metabolic adaptation
to reduced energy expenditure. To save energy in hypoxic condi-
tions, cells downregulate nonessential anabolic or energy-con-
suming processes such as protein synthesis, folding, and degra-
dation (‘‘metabolic arrest’’), ion pump activity (‘‘channel arrest’’),
and other processes (Carey et al., 2003) (Figure 4). Initiation of
translation is carried out by eukaryotic initiation factors (eIF), of
which eIF2 and eIF4E are critical regulators of the preinitiation
and cap-binding complex, respectively. Only inactivation of the
eIF4F complex is regulated by HIF-1a in hypoxia (Liu and Simon,18 Cell Metabolism 9, January 7, 2009 ª2009 Elsevier Inc.2004). This results from the sequestration of its subunit eIF4E by
4E-BP1, when the latter is hypophosphorylated. HIF-1a controls
this process by upregulating Redd1, an inhibitor of mTOR, which
normally phosphorylates 4E-BP1 and thereby inactivates eIF4F
(Brugarolas et al., 2004). Hypoxic tumor and other cells use this
mechanism of oxygen conformance to survive in low O2 condi-
tions. To what extent and which energy conservation mecha-
nisms are operational in PHD1-deficient muscle remains to be
further studied.
Role of PHDs in Hypoxia Tolerance: Consequences
for Ischemic Diseases
The role of PHDs in O2 conformance has implications for
hypoxia tolerance in ischemic conditions. This is exemplified
by treatment of healthy mice with PHD/FIH inhibitors, which
increases viability in (sub)lethal hypoxia, in part via upregulation
of HIF-1a (Kasiganesan et al., 2007). Moreover, genetic studies
in mice reveal that, upon permanent or transient ligation of
supply arteries, or strenuous (ischemic) muscle exercise,
muscle fibers, especially the ones relying on oxidative metabo-
lism, in PHD1-deficient mice are almost completely protected
against ischemic demise (Aragones et al., 2008) (Figure 3).
Remarkably, this hypoxia tolerance is not attributable to an
increase in O2 supply through enhanced angiogenesis, vasodi-
lation, or erythropoiesis, or a shift in muscle fiber from oxidative
to glycolytic type, but, as explained below, to a depression of
metabolism, which protects ischemic cells from lethal cellular
oxidative damage.
It is well known that O2 is of vital importance, yet also carries
an inherent risk of toxicity. One theory even postulates that mito-
chondria became symbiont in hosts to escape possible delete-
rious effects of increasing O2 tension in the earth’s atmosphere,
while the low intrauterine O2 tension might be an adaptation to
protect the immature fetus against O2 toxicity (Singer and Muhl-
feld, 2007). Also, Joseph Priestly, another scientist credited with
the discovery of O2, wasmindful of the toxicity of O2, writing ‘‘For
as a candle burns much faster in dephlogisticated (O2 enriched)
than in common air, so we might live out too fast, and the animal
powers be too soon exhausted in this pure kind of air.’’ This
toxicity of O2 relates to the generation of ROS. The latter are
generated as a result of electron leakage from the mitochondrial
electron transfer chain during normal respiration (Kulkarni et al.,
2007). A long-existing, though debated, model postulates that
mitochondria are able to generate increased amounts of ROS
under hypoxic conditions (Brunelle et al., 2005; Guzy et al.,
2005; Mansfield et al., 2005). When excessive, formation of
ROS in ischemic and ischemia-reperfusion events causes irre-
versible cellular damage and death. Notably, loss of PHD1
protects ischemic muscle fibers against such O2 toxicity (Ara-
gones et al., 2008), as explained in the next paragraph.
Upon ligation of the supply artery in wild-type mice, staining of
myofibers for the hypoxia marker pimonidazole reveals that my-
ofibers, despite being deprived of their O2 supply by 70%,
continue to consume O2 (Aragones et al., 2008). Also, measure-
ments of the reduced versus oxidized fraction of the antioxidant
glutathione, of themuscle area that stains for 8-hydroxy-2-deoxy
guanosine, a marker of deoxyguanosine oxidation, and of the
level of protein carbonylation reveal that ischemic myofibers in
wild-type mice generate large amounts of toxic ROS, that
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enzyme that is highly sensitive to oxidative stress, becomes
inactive in ischemic myofibers, which also exhibit severe ultra-
structural signs of mitochondrial damage.
In contrast, ischemic PHD1-deficient myofibers do not
become pimonidazole positive, consistent with findings that
these cells consume less O2 in baseline conditions (see above).
Also, when using the above-mentioned assays, no or only
minimal signs of oxidative stress can be detected in ischemic
PHD1 mutant muscle. Hence, these findings suggest that,
because of their reduced O2 consumption, PHD1-deficient mito-
chondria exhibit a reduced electron transport and therefore
generate less oxidative stress in ischemic conditions; this
protects cell organelles against destruction. Indeed, ischemic
PHD1-deficient myofibers have normal levels of active aconi-
tase, and also do not exhibit ultrastructural signs of mitochon-
drial degeneration. Furthermore, in vivo 13C-NMR measure-
ments of [13C] glutamate resonances in muscle extracts after
infusion of [U-13C6] glucose indicate that, compared to ischemic
wild-type myofibers, ischemic PHD1-deficient myofibers better
preserve mitochondrial respiration (glucose oxidation), and are
capable of regenerating ATP already within minutes after acute
ischemia (Aragones et al., 2008). Hence, by switching from
aerobic to anaerobic metabolism, and by slowing down mito-
chondrial respiration, PHD1-deficient cells protect themselves
against deleterious effects of oxidative damage in hypoxic
conditions (Aragones et al., 2008; Kim et al., 2006) (Figure 3).
Notably, even transient silencing of PHD1 rapidly induces
hypoxia tolerance and protection against ischemic damage,
warranting further evaluation of PHD1 inhibitors for therapy of
ischemic disease (Aragones et al., 2008) (Figure 3). Pharmacolo-
gical inhibition of PHDs/FIH also exhibits cytoprotection against
ischemia/reperfusion injury (Hill et al., 2008; Ockaili et al.,
2005). An outstanding question is whether PHDs/FIH may
provide ischemic protection via other mechanisms, for instance,
by regulating mechanisms of ischemic preconditioning. Some
recent studies indeed suggest a role of the PHD/HIF pathway
in this process. For instance, myocardial ischemic precondition-
ing is lost upon silencing of HIF-1a versus enhanced upon
silencing of PHD2 (Eckle et al., 2008). Moreover, pharmacolo-
gical inhibition of PHDs/FIH induces myocardial preconditioning
in vivo (Philipp et al., 2006).
Notably, silencing of PPARa abrogates the protection of
PHD1-deficient myofibers against ischemic damage after
femoral artery ligation, indicating that PPARa is essential for
ischemia tolerance (Aragones et al., 2008). Conversely, pharma-
cological activation of PPARa, by agonists such as fenofibrate,
protects skeletal muscle in wild-type mice against ischemic
injury (Aragones et al., 2008). This beneficial effect is also found
in other organs, such as the heart and liver, where PPARa has
a key role in ischemia tolerance (Okaya and Lentsch, 2004;
Yue et al., 2003). The mechanisms underlying the role of PPARa
in ischemia tolerance are not completely understood, and may
differ form one organ to another. As explained above, in PHD1-
deficient skeletal muscle, PPARa-dependent upregulation of
PDK4 seems to contribute to hypoxia tolerance by attenuation
of glucose oxidation, O2 consumption, and mitochondrial ROS
formation (Aragones et al., 2008). The role of PPARa in ischemia
tolerance needs, however, further study, as transgenic animalswith supraphysiological levels of PPARa in the heart are, in
fact, more susceptible to ischemia/reperfusion injury (Samban-
dam et al., 2006); whether this suggests gene dosage-depen-
dent activities of PPARa in this process remains to be explored.
Metabolic Regulation of Aging by PHDs/FIH
Senescence, a state of irreversible growth arrest, has been
linked to oxidative metabolism and stress (including oxidative
damage of mitochondrial DNA (Druzhyna et al., 2008), and is
counteracted by hypoxia, likely through mechanisms mediating
hypoxia tolerance. Of note, hypoxia tolerance is reduced in
elderly (Mariani et al., 2000) and associated with impaired
hypoxia-inducible gene expression (Di Giulio et al., 2005).
Hypoxia increases the expression of a telomerase in a HIF-1a-
dependent manner, thereby opposing age-related telomere
shortening (Yatabe et al., 2004). The role of PHDs in oxidative
metabolism and oxygen conformance may therefore explain
why PHD2 induces cell senescence through repression of HIF
activity (Kato et al., 2006). Expression of PHD3 is also upregu-
lated in aging rodents; this induction is counteracted by caloric
restriction (Rohrbach et al., 2008) that promotes longevity. The
protection against oxidative stress in the absence of PHD1 (Ara-
gones et al., 2008) versus the aggravated oxidative stress inmice
lacking HIF-2a (Scortegagna et al., 2003) further warrant analysis
of O2 sensing pathways in senescence. Also, the age-associated
increase of PHD3 expression inversely correlates with the
expression of macrophage migration inhibitory factor, a HIF
target that inhibits cellular senescence (Rohrbach et al., 2008;
Welford et al., 2006).
Perspectives
It is evident from the above discussion that PHDs/FIH are impor-
tant multitasking regulators of metabolism, with far reaching
impact on processes such as metabolic fuel selection, oxidative
performance, oxidative stress, hypoxia tolerance, hibernation,
and others. Considering the involvement of these processes in
numerous medical disorders, ranging from ischemic heart
disease, stroke, inflammatory disorders, cancer, and various
metabolic disorders, further study of the distinct role of these
O2 sensors is warranted. A better understanding of their (patho)-
physiological role will also aid in the preclinical development of
therapeutic strategies, based on the use of selective PHD/FIH
inhibitors.
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